PL376557A1 - Postacie krystaliczne pitawastatyny wapnia - Google Patents

Postacie krystaliczne pitawastatyny wapnia

Info

Publication number
PL376557A1
PL376557A1 PL376557A PL37655704A PL376557A1 PL 376557 A1 PL376557 A1 PL 376557A1 PL 376557 A PL376557 A PL 376557A PL 37655704 A PL37655704 A PL 37655704A PL 376557 A1 PL376557 A1 PL 376557A1
Authority
PL
Poland
Prior art keywords
crystalline forms
pitavastatin calcium
pitavastatin
calcium
quinolin
Prior art date
Application number
PL376557A
Other languages
English (en)
Polish (pl)
Inventor
Der Schaaf Paul Adriaan Van
Fritz Blatter
Martin Szelagiewicz
Kai-Uwe Schöning
Original Assignee
Ciba Specialty Chemicals Holding Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32865094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL376557(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Specialty Chemicals Holding Inc. filed Critical Ciba Specialty Chemicals Holding Inc.
Publication of PL376557A1 publication Critical patent/PL376557A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
PL376557A 2003-02-12 2004-02-02 Postacie krystaliczne pitawastatyny wapnia PL376557A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03405080 2003-02-12

Publications (1)

Publication Number Publication Date
PL376557A1 true PL376557A1 (pl) 2006-01-09

Family

ID=32865094

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376557A PL376557A1 (pl) 2003-02-12 2004-02-02 Postacie krystaliczne pitawastatyny wapnia

Country Status (10)

Country Link
US (15) US20060142582A1 (https=)
EP (3) EP1592668A1 (https=)
JP (13) JP5192147B2 (https=)
CN (3) CN102285916B (https=)
AU (1) AU2004212160B2 (https=)
CA (2) CA2785954A1 (https=)
DE (1) DE202004021379U1 (https=)
PL (1) PL376557A1 (https=)
TW (4) TW201514149A (https=)
WO (1) WO2004072040A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202004021379U1 (de) * 2003-02-12 2008-02-21 Ciba Specialty Chemicals Holding Inc. Kristalline Formen von Pitivastatin Calcium
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
AU2013204129C1 (en) * 2003-12-26 2017-03-02 Nissan Chemical Industries, Ltd. Crystal Form of Quinoline Compound and Process for its Production
EP1711493A2 (en) * 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
WO2006079611A1 (en) * 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
US20120022102A1 (en) 2010-01-20 2012-01-26 Cadila Healthcare Limited Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof
WO2012025939A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Pitavastatin calcium and process for its preparation
EP3178812A1 (en) 2010-11-12 2017-06-14 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
WO2012106584A2 (en) * 2011-02-04 2012-08-09 Dr. Reddy's Laboratories Ltd. Pitavastatin salts
ITMI20111475A1 (it) * 2011-08-02 2013-02-03 Dipharma Francis Srl Forme cristalline di pitavastatina sale di calcio
EA024991B1 (ru) * 2011-09-12 2016-11-30 ФАРМА ДжРС, Д.О.О. Полиморфная форма питавастатина кальция
MX356344B (es) * 2011-10-20 2018-05-23 Oryzon Genomics Sa Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1.
WO2013098773A1 (en) * 2011-12-28 2013-07-04 Dr. Reddy's Laboratories Limited Crystalline forms of pitavastatin calcium
CN104844506A (zh) * 2015-05-15 2015-08-19 苗怡文 一种治疗高血脂症的药物匹伐他汀钙化合物
CN104860882A (zh) * 2015-05-15 2015-08-26 苗怡文 一种治疗高血脂症的药物匹伐他汀钙组合物
CN105213319A (zh) * 2015-09-17 2016-01-06 青岛华之草医药科技有限公司 一种降血脂药物匹伐他汀钙组合物干混悬剂
CN105125504A (zh) * 2015-09-17 2015-12-09 青岛华之草医药科技有限公司 一种降血脂药物匹伐他汀钙组合物颗粒剂
US10937978B2 (en) * 2016-02-25 2021-03-02 University Of Louisville Research Foundation, Inc. Methods for forming a perovskite solar cell
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
CN109053568A (zh) * 2018-08-29 2018-12-21 南京卓康医药科技有限公司 一种高纯度匹伐他汀钙新晶型及其制备方法
CN113834795B (zh) * 2020-06-08 2024-12-03 上海医药集团股份有限公司 硫酸羟氯喹颗粒水分近红外光谱在线定量模型及其建立方法及检测方法
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
WO2023049312A1 (en) * 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms
CN116969884A (zh) * 2023-07-28 2023-10-31 河北广祥制药有限公司 一种匹伐他汀钙单晶及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3175944A (en) * 1956-06-18 1965-03-30 Upjohn Co Dihydronovobiocin and derivatives thereof
JPS61171460A (ja) 1985-01-23 1986-08-02 Dainippon Pharmaceut Co Ltd 塩酸メクロフエノキサ−ト１型結晶の製造法
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
ES2115725T3 (es) 1992-07-31 1998-07-01 Shionogi & Co Hidrocloruro de triazoliltiometiltiocefalosporina, su hidrato cristalino y la preparacion de este.
JP2575590B2 (ja) 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
GB9324931D0 (en) * 1993-12-04 1994-01-26 Pfizer Ltd Glutaramide derivatives
DE69526784T2 (de) 1994-02-25 2002-09-05 Daicel Chemical Industries, Ltd. Verfahren zur herstellung von optisch aktiven mevalonolactonen
JP3558684B2 (ja) 1994-06-28 2004-08-25 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の乾燥方法
US6335449B1 (en) * 1998-07-23 2002-01-01 Nissan Chemical Industries, Ltd. Process for the preparation of quinoline derivative and intermediate therefor
JP4749533B2 (ja) * 1999-09-30 2011-08-17 大塚化学株式会社 セファロスポリン結晶
PL361912A1 (en) * 2000-10-31 2004-10-04 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
CA2427255A1 (en) * 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
EP1345903A1 (en) * 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
HRPK20040255B3 (en) * 2001-08-16 2006-02-28 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
AU2003226971B2 (en) * 2002-01-31 2006-11-30 Novartis Ag Process for the manufacture of HMG-CoA reductase inhibitors
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
AU2003231361A1 (en) 2002-04-17 2003-10-27 Yamanouchi Pharmaceutical Co., Ltd. Novel crystal of quinoxalinedione derivative anhydride
GB0210234D0 (en) 2002-05-03 2002-06-12 Novartis Ag Process for the manufacture of organic compounds
DE202004021379U1 (de) * 2003-02-12 2008-02-21 Ciba Specialty Chemicals Holding Inc. Kristalline Formen von Pitivastatin Calcium
TWI328006B (en) 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
CN100344422C (zh) * 2006-05-11 2007-10-24 朱能国 用人工用材林松木及其板材生产阻燃防潮装饰板材的方法
JP5353678B2 (ja) * 2009-12-17 2013-11-27 トヨタ自動車株式会社 車両の制御装置

Also Published As

Publication number Publication date
DE202004021379U1 (de) 2008-02-21
JP2014062115A (ja) 2014-04-10
JP2006518354A (ja) 2006-08-10
US20140364614A1 (en) 2014-12-11
EP3299359A1 (en) 2018-03-28
JP2014055185A (ja) 2014-03-27
TW201514149A (zh) 2015-04-16
US20130053413A1 (en) 2013-02-28
US20160024010A1 (en) 2016-01-28
JP5500305B2 (ja) 2014-05-21
TW201345893A (zh) 2013-11-16
JP2016222737A (ja) 2016-12-28
JP2014205723A (ja) 2014-10-30
CN1747934A (zh) 2006-03-15
TW201213311A (en) 2012-04-01
JP2014024848A (ja) 2014-02-06
WO2004072040A1 (en) 2004-08-26
EP2500339A1 (en) 2012-09-19
US20060142582A1 (en) 2006-06-29
CA2785954A1 (en) 2004-08-26
JP5445713B2 (ja) 2014-03-19
AU2004212160B2 (en) 2009-05-14
US20200148644A1 (en) 2020-05-14
CN101219992A (zh) 2008-07-16
JP2015172086A (ja) 2015-10-01
US20120101126A1 (en) 2012-04-26
TWI485135B (zh) 2015-05-21
JP2013177466A (ja) 2013-09-09
US8853405B2 (en) 2014-10-07
US20210002227A1 (en) 2021-01-07
US20230322680A1 (en) 2023-10-12
US8557993B2 (en) 2013-10-15
JP5192147B2 (ja) 2013-05-08
US20140005402A1 (en) 2014-01-02
US20090182008A1 (en) 2009-07-16
TW200420541A (en) 2004-10-16
CN102285916B (zh) 2015-02-25
CA2513837A1 (en) 2004-08-26
JP5702494B2 (ja) 2015-04-15
AU2004212160A1 (en) 2004-08-26
JP2014198743A (ja) 2014-10-23
US20180029987A1 (en) 2018-02-01
JP5366163B2 (ja) 2013-12-11
JP2011201915A (ja) 2011-10-13
JP2019031574A (ja) 2019-02-28
CN100374422C (zh) 2008-03-12
JP2020169196A (ja) 2020-10-15
JP2018044009A (ja) 2018-03-22
US20220169614A1 (en) 2022-06-02
US20190256469A1 (en) 2019-08-22
US20170022163A1 (en) 2017-01-26
US20180346425A1 (en) 2018-12-06
CN102285916A (zh) 2011-12-21
CN101219992B (zh) 2011-08-31
EP1592668A1 (en) 2005-11-09

Similar Documents

Publication Publication Date Title
PL376557A1 (pl) Postacie krystaliczne pitawastatyny wapnia
SI1682536T1 (sl) Postopek izdelave kalcijeve soli rosuvastatin-(E)-7-(4-(4-fluorofenil) -6-izopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il) (3r,5s)-3,5- dihidroksihept-6-enojske kisline in njenih kristalnih vmesnih spojin
SI1263739T1 (sl) Kristalinicne soli (E)-7-(4-(4-fluorofenil)-6-izopril-2- (metil(metilsulfonil)amino)pirimidin-5-il)-(3R,5S)-3,5-dihidroksihept- 6-enojske kisline
TW200631944A (en) Potassium salt of an HIV integrase inhibitor
DK1663989T3 (da) Krystallisk form af bis(E)-7-[4(4-fluorphenyl)-6-isopropyl-2-methyl(methylsulfonyl)aminopyrimidin-5-yl(3R,5S))-3-5-dihydroxyhept-6-ensyrecalciumsalt
WO2005046589A3 (en) Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
EP1954287A4 (en) CETP INHIBITORS
EA200601364A1 (ru) Производные хинолина и их применение в качестве ингибиторов микобактерий
MXPA06000725A (es) Sal de acido (2s-4s)-4 -fluoro-1 -[4-fluoro- beta-(4- fluorofenil) -l-fenilalanil] -2-pirrolidincarbonitril p-toluenosulfonico y formas cristalinas anhidras del mismo.
AU2006260148A8 (en) Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)- 7-methoxy-6-quinolinecarboxamide and process for producing the same
AU2002950217A0 (en) 8- Hydroxy Quinoline Derivatives
AU2003230192A1 (en) Novel crystalline forms of aripiprazole
EA200400414A1 (ru) Кристаллические гидраты производных анилида никотиновой кислоты
AU2003209043A1 (en) Novel anhydrous amorphous forms of montelukast sodium salt
TW200640913A (en) 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
MY148393A (en) Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
PL1704144T3 (pl) Sposób wytwarzania soli wapniowej kwasu (E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo](3R,5S)-3,5-dihydroksy-6-heptenowego
EP1275388A4 (en) Tnf- alpha inhibitors
PE20060767A1 (es) Derivados de tetrahidroquinolina como inhibidores de cept
WO2006064269A3 (en) Salts of leukotriene antagonist montelukast
UA108408C2 (ru) Способ получения солей розувастатина
WO2004091278A3 (en) Gabapentin compositions
UA91549C2 (ru) Производные хинолина как антибактериальные агенты
EP1650189A4 (en) benzylamine
CA2419178A1 (en) Cytokine production inhibitor